74 related articles for article (PubMed ID: 24126923)
21. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.
Na II; Rho JK; Choi YJ; Kim CH; Park JH; Koh JS; Ryoo BY; Yang SH; Lee JC
Lung Cancer; 2007 Jul; 57(1):96-102. PubMed ID: 17337084
[TBL] [Abstract][Full Text] [Related]
22. Intraoperative pleural lavage: is it a valid prognostic factor in lung cancer?
Vicidomini G; Santini M; Fiorello A; Parascandolo V; Calabrò B; Pastore V
Ann Thorac Surg; 2005 Jan; 79(1):254-7; discussion 254-7. PubMed ID: 15620952
[TBL] [Abstract][Full Text] [Related]
23. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
24. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
25. High expression of truncated GLI3 is associated with poor overall survival in patients with non-small cell lung cancer.
Bai XY; Lin JY; Zhang XC; Xie Z; Yan HH; Chen ZH; Xu CR; An SJ; Sheng GM; Wu YL
Cancer Biomark; 2013; 13(1):37-47. PubMed ID: 23736020
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer.
Gu J; Ding JY; Lu CL; Lin ZW; Chu YW; Zhao GY; Guo J; Ge D
Lung Cancer; 2013 Aug; 81(2):259-65. PubMed ID: 23706417
[TBL] [Abstract][Full Text] [Related]
27. Favorable prognosis of operable non-small cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs).
Pircher A; Fiegl M; Untergasser G; Heidegger I; Medinger M; Kern J; Hilbe W
Lung Cancer; 2013 Aug; 81(2):252-8. PubMed ID: 23664449
[TBL] [Abstract][Full Text] [Related]
28. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients.
Melloni G; Ferreri AJ; Russo V; Gattinoni L; Arrigoni G; Ceresoli GL; Zannini P; Traversari C
Oncol Rep; 2004 Jul; 12(1):145-51. PubMed ID: 15201976
[TBL] [Abstract][Full Text] [Related]
30. Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer.
Soria JC; Moon C; Kemp BL; Liu DD; Feng L; Tang X; Chang YS; Mao L; Khuri FR
Clin Cancer Res; 2003 May; 9(5):1785-91. PubMed ID: 12738735
[TBL] [Abstract][Full Text] [Related]
31. The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung.
Anton RC; Coffey DM; Gondo MM; Stephenson MA; Brown RW; Cagle PT
Mod Pathol; 2000 Nov; 13(11):1167-72. PubMed ID: 11106072
[TBL] [Abstract][Full Text] [Related]
32. LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer.
Li J; Shi SB; Shi WL; Wang Y; Yu LC; Zhu LR; Ge LP
Transl Res; 2014 Jan; 163(1):27-35. PubMed ID: 24120632
[TBL] [Abstract][Full Text] [Related]
33. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome.
Zhang L; Chen J; Ke Y; Mansel RE; Jiang WG
Int J Mol Med; 2006 May; 17(5):937-44. PubMed ID: 16596284
[TBL] [Abstract][Full Text] [Related]
34. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
35. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer.
Chang YS; Kong G; Sun S; Liu D; El-Naggar AK; Khuri FR; Hong WK; Lee HY
Clin Cancer Res; 2002 Dec; 8(12):3796-802. PubMed ID: 12473592
[TBL] [Abstract][Full Text] [Related]
37. [Analysis of prognostic factors in 1826 patients with completely resected non-small cell lung cancer].
Gao YS; Xing XZ; Shao K; Feng XL; He J
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):134-7. PubMed ID: 18646698
[TBL] [Abstract][Full Text] [Related]
38. Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer.
Shah A; Swain WA; Richardson D; Edwards J; Stewart DJ; Richardson CM; Swinson DE; Patel D; Jones JL; O'Byrne KJ
Clin Cancer Res; 2005 Apr; 11(8):2930-6. PubMed ID: 15837744
[TBL] [Abstract][Full Text] [Related]
39. [The expression of O6-methylguanine DNA methyltransferase and p53 in non-small cell lung cancer and the association with the prognosis].
Liu Y; Wang J; Zhang H; Fu XM; Wang HQ
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jun; 33(6):427-31. PubMed ID: 20979814
[TBL] [Abstract][Full Text] [Related]
40. Maspin gene expression is a significant prognostic factor in resected non-small cell lung cancer (NSCLC). Maspin in NSCLC.
Katakura H; Takenaka K; Nakagawa M; Sonobe M; Adachi M; Ito S; Wada H; Tanaka F
Lung Cancer; 2006 Mar; 51(3):323-8. PubMed ID: 16406136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
